Transient receptor potential channels in multiple myeloma.

Area of Science:

• Oncology
• Molecular Biology
• Calcium Signaling

Background:

• Multiple myeloma is a prevalent, incurable hematologic malignancy with incompletely understood molecular drivers.
• Intracellular calcium ions are key signaling molecules; dysregulated calcium homeostasis promotes cancer survival and drug resistance.
• Transient Receptor Potential (TRP) channels, critical regulators of calcium signaling, are implicated in various cancer cell behaviors.

Purpose of the Study:

• To review the multifaceted roles of TRP channels in multiple myeloma.
• To explore TRP channel involvement in disease progression, metastasis, bone destruction, and drug resistance.
• To identify potential TRP channel-based therapeutic targets and prognostic markers.

Main Methods:

• Literature review synthesizing current research on TRP channels in multiple myeloma.
• Analysis of studies detailing specific TRP channel functions (e.g., TRPV1, TRPV2, TRPM7, TRPV4, TRPC1, TRPA1).
• Examination of evidence linking TRP channels to clinical outcomes and therapeutic responses.

Main Results:

• TRPV1 and TRPV2 channels drive multiple myeloma progression.
• TRPM7 promotes cancer cell dissemination, while TRPV2 and TRPV4 contribute to myeloma-associated bone destruction.
• TRP channel modulation shows promise in enhancing chemotherapy (e.g., TRPV1 inhibition, TRPV2 activation with bortezomib) and predicting drug response (TRPC1 with MTI-101).
• TRPA1 antagonism may mitigate bortezomib-induced neuropathy.

Conclusions:

• TRP channels are integral to multiple myeloma pathogenesis and clinical characteristics.
• Specific TRP channels represent promising therapeutic targets for multiple myeloma treatment.
• TRP channel activity may serve as biomarkers for prognosis and drug responsiveness in multiple myeloma patients.